Internetiühendust pole — kuvatakse lehe salvestatud versioon.

Silence Therapeut…

USUSD
← Aktsiafiltri Juurde

Silence Therapeutics PLC (US:SLNCF) — Biotechnology: Pharmaceutical Preparations. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 1. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.

Ettevõtte Kohta

Veebileht
silence-therapeutics.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Peakontor
LONDON, United Kingdom
Tegevjuht
Iain Gladstone Ross
Töötajad
88
Ringluses Olevad Aktsiad
141.74 mln seisuga 2026-07-31
Vabalt Kaubeldavad Aktsiad
37.84 mln
Turukapitalisatsioon
665.67 mln USD
Siseringi Isikud
7.97%
Institutsionaalsed Investorid
39.68%
Tegevusala (SIC)
Pharmaceutical Preparations
FCF
−42.3 mln USD
Võlg
?
Kasum ja FCF — 12 kuu jooksul kuni 30.06.2026 (ettevõtte viimane raport).
NAV
0.27 USD · P/NAV 14.2
Bilansikuupäev30.06.2026
Varad106 mln USD
− Kohustused67.9 mln USD
= NAV (Ettevõtte Aktsionäride Omakapital)38.5 mln USD
− Firmaväärtus10.3 mln USD
= Materiaalne NAV28.1 mln USD
Aktsiad141 739 180
NAV Aktsia Kohta0.27 USD
Käegakatsutav NAV Aktsia Kohta0.20 USD
Aktsia Hind (SLNCF)3.8500 USD
P/NAV14.18
NAV Ajalugu
BilansikuupäevNAVNAV Aktsia Kohta
30.06.202638.5 mln USD0.27 USD
31.03.202649.4 mln USD0.35 USD
31.12.202562.3 mln USD0.44 USD
30.09.202574.1 mln USD0.52 USD
30.06.202594.2 mln USD0.66 USD
31.03.2025113 mln USD0.80 USD
31.12.2024134 mln USD0.95 USD
30.09.2024127 mln USD0.89 USD
Kirjeldus

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

reklaam

Börsid ja Tikkerid

BörsTikkerValuutaHindTüüp
US USA StocksSLNCFUSD3.85 -3.75%tavalised aktsiad

Hind 3 Kuu Jooksul

3M1Y3Y5Y
US:SLNCF · USD
tõususepäev langusepäevViige kursor / puudutage päeva — avamis-, sulgemis-, kõrgeim ja madalaim hind

Suurimad Omanikud

OmanikOsalusAktsiadAruande Kuupäev
Siren, L.L.C.5.5%3.31 mln2026-06-30
TCG Crossover Management…5.04%3.03 mln2026-06-30
Redmile Group, LLC3.6%2.16 mln2026-06-30
Nantahala Capital Manage…2.24%1.35 mln2026-06-30
Citadel Advisors Llc2.21%1.33 mln2026-06-30
Nextech Invest, Ltd.1.58%952 4002026-06-30
Millennium Management Ll…1.51%909 2792026-06-30
Ikarian Capital, LLC1.38%830 7842026-06-30
Tetragon Partners GP Ltd…1.27%764 2562026-06-30
Soleus Capital Managemen…1.05%630 0002026-06-30
Fidelity Advisor Series…0.8%482 0882026-07-31
iShares Trust-iShares Bi…0.39%234 0092026-08-31
ALGER FUNDS-Alger Small…0.18%105 6792026-07-31
Fidelity Select Portfoli…0.17%103 9122026-07-31
ALGER INSTITUTIONAL FUND…0.07%41 2922026-07-31
Fidelity Concord Street…0.05%29 5382026-07-31
SPDR INDEX SHARES Fd.S-S…0.02%9 5322026-06-30
Trust for Professional M…0.01%8 6952026-05-31
Steward Funds Inc-Stewar…0.01%5 8002026-07-31
Invesco Exchange-Traded…0%2 9182026-08-31